Frank Jessen

Frank Jessen's AcademicInfluence.com Rankings

Frank Jessen

Philosophy

#6913

World Rank

#10035

Historical Rank

Logic

#4001

World Rank

#5241

Historical Rank

philosophy Degrees

Frank Jessen

Biology

#9397

World Rank

#12598

Historical Rank

Neuroscience

#1370

World Rank

#1417

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Frank Jessen's Degrees

PhD Neuroscience University of Cologne
Doctorate Medicine University of Cologne

Why Is Frank Jessen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Frank Jessen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018) (4523)
Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease (2011) (1701)
Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease (2009) (1644)
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease (2014) (1634)
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes (2009) (1441)
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2013) (1388)
Defeating Alzheimer's disease and other dementias: a priority for European science and society (2016) (1172)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010) (616)
Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease (2010) (587)
Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. (2010) (572)
AD dementia risk in late MCI, in early MCI, and in subjective memory impairment (2014) (401)
The characterisation of subjective cognitive decline (2020) (383)
Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. (2000) (375)
Implementation of subjective cognitive decline criteria in research studies (2017) (333)
Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population (2009) (331)
Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. (2015) (296)
Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease (2011) (292)
Nitration of Tyrosine 10 Critically Enhances Amyloid β Aggregation and Plaque Formation (2011) (263)
A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats (2012) (254)
Volume reduction of the entorhinal cortex in subjective memory impairment (2006) (249)
New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) (246)
Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors (2012) (227)
24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. (2002) (223)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
The future of Alzheimer's disease: The next 10 years (2011) (203)
Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load (2007) (198)
Risk of dementia in elderly patients with the use of proton pump inhibitors (2015) (193)
A genetic variation of the inflammatory cytokine interleukin‐6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease (1999) (193)
The Concreteness Effect: Evidence for Dual Coding and Context Availability (2000) (191)
Mild Cognitive Impairment in General Practice: Age-Specific Prevalence and Correlate Results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe) (2007) (189)
Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia (2018) (188)
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial (2013) (178)
Deep Brain Stimulation for Tourette-Syndrome: A Systematic Review and Meta-Analysis (2016) (173)
Prevalence and risk factors for depression in non-demented primary care attenders aged 75 years and older. (2008) (173)
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study (2010) (173)
Convergent genetic and expression data implicate immunity in Alzheimer's disease (2014) (172)
Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD (2000) (164)
Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding (2007) (158)
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease (2012) (158)
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. (2007) (157)
Volume Loss of the Medial Temporal Lobe Structures in Subjective Memory Impairment (2010) (155)
Plasma 24S‐hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease (2000) (153)
Patterns of subjective memory impairment in the elderly: association with memory performance (2007) (144)
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment (2012) (142)
Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. (2009) (138)
Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease (2002) (138)
Glucose metabolism, gray matter structure and memory decline in subjective memory impairment (2012) (136)
Evidence of neuronal compensation during episodic memory in subjective memory impairment. (2011) (134)
Longitudinal Predictors of Institutionalization in Old Age (2015) (134)
Prediction of Dementia in Primary Care Patients (2011) (130)
Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type (2015) (129)
Gray matter atrophy pattern in elderly with subjective memory impairment (2014) (129)
A peripheral epigenetic signature of immune system genes is linked to neocortical thickness and memory (2017) (126)
Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. (2001) (122)
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study (2015) (119)
Reduced hippocampal activation during encoding and recognition of words in schizophrenia patients. (2003) (119)
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. (2007) (115)
KIBRA gene variants are associated with episodic memory in healthy elderly (2008) (111)
Cognitive performance before and after the onset of subjective cognitive decline in old age (2015) (110)
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE) (2018) (109)
Multicenter assessment of reliability of cranial MRI (2006) (108)
Amplitude reduction of the mismatch negativity in first-degree relatives of patients with schizophrenia (2001) (107)
Evidence for an association between KIBRA and late-onset Alzheimer's disease (2010) (105)
Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease (2014) (105)
DNA sequence variants of the FKBP5 gene are associated with unipolar depression. (2010) (104)
Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study (2011) (103)
Anticholinergic drug use and risk for dementia: target for dementia prevention (2010) (102)
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study (2008) (101)
Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing (2010) (101)
Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke (2004) (101)
Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction (2006) (101)
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease (2020) (98)
Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. (2013) (96)
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy (2020) (94)
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease (2013) (93)
Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration (2014) (93)
Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene (2014) (92)
S-Adenosylmethionine Is Decreased in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease (2010) (90)
In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults (2017) (89)
Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients (2001) (89)
Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment (2009) (88)
Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations (2017) (88)
Converging Genetic and Functional Brain Imaging Evidence Links Neuronal Excitability to Working Memory, Psychiatric Disease, and Brain Activity (2014) (86)
In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. (2016) (86)
Age-related functional changes in domain-specific medial temporal lobe pathways (2018) (86)
Apart from nihilism and stigma: what influences general practitioners' accuracy in identifying incident dementia? (2009) (86)
Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment (2016) (86)
TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2017) (85)
Neural correlates of verbal episodic memory in patients with MCI and Alzheimer's disease––a VBM study (2008) (85)
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2021) (85)
Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease (1999) (83)
In-vivo proton MR-spectroscopy of the human brain: Assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration (2002) (83)
Resting-state perfusion in nonmedicated schizophrenic patients: a continuous arterial spin-labeling 3.0-T MR study. (2010) (81)
METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research (2016) (81)
Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease (2016) (80)
A multicenter 1H-MRS study of the medial temporal lobe in AD and MCI (2009) (80)
Apolipoprotein E epsilon 4 genotype and a physically active lifestyle in late life: analysis of gene–environment interaction for the risk of dementia and Alzheimer's disease dementia (2013) (79)
APOA1 polymorphism influences risk for early‐onset nonfamiliar AD (2005) (79)
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease (2020) (78)
Interrelated neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state (2008) (78)
Activation of human language processing brain regions after the presentation of random letter strings demonstrated with event-related functional magnetic resonance imaging (1999) (77)
CSF cortisol in Alzheimer's disease and mild cognitive impairment (2009) (77)
The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease (2010) (75)
Treatment monitoring and response prediction with proton MR spectroscopy in AD (2006) (74)
Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia (2006) (74)
ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia (2005) (74)
Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. (2009) (73)
Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population (2000) (72)
Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease (2018) (71)
Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data (2017) (70)
Prognosis of Mild Cognitive Impairment in General Practice: Results of the German AgeCoDe Study (2014) (70)
Early-Onset and Late-Onset Depression Are Independent of the Genetic Polymorphism of Apolipoprotein E (1999) (69)
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer (2017) (69)
Subjective Cognitive Decline (2015) (68)
Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. (2002) (67)
Unipolar depression and hippocampal volume: Impact of DNA sequence variants of the glucocorticoid receptor gene (2008) (67)
N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. (2013) (66)
Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study (2019) (66)
Abnormal Resting-State Functional Connectivity Strength in Mild Cognitive Impairment and Its Conversion to Alzheimer's Disease (2015) (65)
Erratum: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2009) (64)
Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease (2012) (64)
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey (2015) (64)
New insights on the genetic etiology of Alzheimer’s and related dementia (2020) (64)
Smoking upregulates α4β2* nicotinic acetylcholine receptors in the human brain (2008) (63)
Cortical thinning in individuals with subjective memory impairment. (2015) (62)
Mild cognitive impairment (MCI) and actual retrieval performance affect cerebral activation in the elderly (2007) (62)
Incident subjective memory complaints and the risk of subsequent dementia (2015) (62)
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. (2012) (61)
Predictors of frailty in old age–results of a longitudinal study (2015) (61)
Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF Aβ levels (2019) (61)
A multicentre RCT on community occupational therapy in Alzheimer's disease: 10 sessions are not better than one consultation (2011) (60)
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia (2017) (60)
Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. (2017) (59)
Prediction of incident dementia: impact of impairment in instrumental activities of daily living and mild cognitive impairment-results from the German study on ageing, cognition, and dementia in primary care patients. (2012) (59)
Mrp14 Deficiency Ameliorates Amyloid β Burden by Increasing Microglial Phagocytosis and Modulation of Amyloid Precursor Protein Processing (2012) (59)
A family study of Alzheimer disease and early- and late-onset depression in elderly patients. (2001) (58)
Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. (2009) (58)
The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy. (2014) (57)
Alterations of cholesterol precursor levels in Alzheimer's disease. (2010) (57)
Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease (2018) (57)
Association of SORL1 gene variants with Alzheimer's disease (2009) (56)
Genome-Wide Association Study of Vascular Dementia (2012) (56)
Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease (2010) (56)
Interaction effects of subjective memory impairment and ApoE4 genotype on episodic memory and hippocampal volume (2011) (56)
Predictors of Costs in Dementia in a Longitudinal Perspective (2013) (56)
Alzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood (2019) (55)
PLD3 in non-familial Alzheimer's disease (2015) (54)
The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. (2013) (53)
Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. (2011) (53)
Do general practitioners recognize mild cognitive impairment in their patients? (2010) (52)
Prospective Associations between Single Foods, Alzheimer’s Dementia and Memory Decline in the Elderly (2018) (50)
No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression (2009) (49)
Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism (2013) (49)
Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease (2014) (49)
Hippocampal Surface Analysis in Subjective Memory Impairment, Mild Cognitive Impairment and Alzheimer’s Dementia (2008) (48)
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI (2012) (47)
The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease (2019) (46)
Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease. (2012) (46)
Longitudinal predictors of informal and formal caregiving time in community-dwelling dementia patients (2016) (45)
Predictors of Institutionalisation in Incident Dementia – Results of the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe Study) (2012) (45)
Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings. (2011) (44)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. (2015) (44)
Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. (2016) (44)
N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: A systematic review (2014) (43)
Functional MRI of cerebral activation during encoding and retrieval of words (1999) (42)
Engineered antibodies: new possibilities for brain PET? (2019) (42)
Anatomical correlates of the neuropsychiatric symptoms in Alzheimer's disease. (2015) (42)
Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive Decline. (2015) (41)
The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease (2011) (41)
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. (2014) (41)
Feature Binding Deficits in Subjective Cognitive Decline and in Mild Cognitive Impairment. (2015) (41)
Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment (2014) (40)
Influence of SORL1 gene variants: Association with CSF amyloid-β products in probable Alzheimer's disease (2008) (40)
Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults (2019) (40)
Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI (2015) (40)
Successful treatment of sexual disinhibition in dementia with carbamazepine -- a case report. (2005) (39)
CYP46A1 variants influence Alzheimer’s disease risk and brain cholesterol metabolism (2009) (39)
Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment (2016) (39)
Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson’s Disease (2015) (39)
Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study (2020) (39)
Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes (2014) (38)
The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk (2014) (38)
Neuroanatomical Characteristics Associated With Response to Deep Brain Stimulation of the Nucleus Basalis of Meynert for Alzheimer's Disease (2018) (37)
Gene polymorphisms in prodynorphin (PDYN) are associated with episodic memory in the elderly (2009) (37)
Anterior hippocampus orchestrates successful encoding and retrieval of non-relational memory: an event-related fMRI study (2008) (36)
Reduced future-oriented decision making in individuals with subjective cognitive decline: A functional MRI study (2017) (36)
Confirmation of the association between bleomycin hydrolase genotype and Alzheimer's disease (2000) (36)
Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing (2018) (36)
Predicting primary progressive aphasias with support vector machine approaches in structural MRI data (2017) (36)
A hierarchy of predictors for dementia‐free survival in old‐age: results of the AgeCoDe study (2014) (35)
Lifetime depressive and somatic symptoms as preclinical markers of late-onset depression (2003) (35)
Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age (2021) (34)
The costs of dementia from the societal perspective: is care provided in the community really cheaper than nursing home care? (2014) (34)
Is function in instrumental activities of daily living a useful feature in predicting Alzheimer's disease dementia in subjective cognitive decline? (2018) (34)
Caspase-8, association with Alzheimer’s Disease and functional analysis of rare variants (2017) (34)
PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment (2020) (34)
A genome-wide survey of human short-term memory (2009) (34)
PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment (2020) (34)
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies (2020) (33)
Risk factors and early signs of Alzheimer's disease in a family study sample (2006) (33)
Association of an interleukin-1β gene polymorphism at position -511 with Alzheimer's disease (2003) (33)
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. (2015) (33)
RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism (2009) (32)
Predictors of hippocampal atrophy in critically ill patients (2015) (32)
Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease (2003) (32)
Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment. (2017) (32)
Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype. (2010) (32)
[Potentially inappropriate medication in elderly primary care patients : A retrospective, longitudinal analysis]. (2013) (32)
Verbal Memory Deficits Are Correlated with Prefrontal Hypometabolism in 18FDG PET of Recreational MDMA Users (2013) (32)
Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. (2008) (31)
A multicenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe (2006) (31)
Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. (2011) (31)
Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease. (2012) (30)
A Comparative Study of the Different N-Acetylaspartate Measures of the Medial Temporal Lobe in Alzheimer’s Disease (2005) (30)
DNA Methylation of the TNF-α Promoter Region in Peripheral Blood Monocytes and the Cortex of Human Alzheimer's Disease Patients (2014) (30)
Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease (2015) (29)
Which types of mental work demands may be associated with reduced risk of dementia? (2017) (29)
Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies (2018) (29)
A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests (2018) (29)
Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD) (2018) (29)
Highly efficient yellow organic light emitting diode based on a layer-cross faded emission layer allowing easy color tuning (2009) (29)
The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease (2015) (29)
Minor neuropsychological deficits in patients with subjective cognitive decline (2020) (29)
Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer’s disease based on multicenter diffusion tensor imaging (2018) (28)
Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples (2019) (28)
Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project (2019) (28)
Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury (2020) (28)
Allelic association between the D10S1423 marker and Alzheimer's disease in a German population (2000) (27)
Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients (2020) (27)
Subjective cognitive decline is longitudinally associated with lower health-related quality of life (2017) (27)
Is the Clock Drawing Test Appropriate for Screening for Mild Cognitive Impairment? – Results of the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe) (2009) (27)
AMYPAD Diagnostic and Patient Management Study: Rationale and design (2018) (27)
Cerebrospinal fluid levels of &bgr;-amyloid(42) in patients with Alzheimer's disease are related to the exon 2 polymorphism of the cathepsin D gene (2002) (27)
Tau plasma levels in subjective cognitive decline: Results from the DELCODE study (2017) (26)
CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk (2008) (26)
[Diagnostic lumbar puncture performed in the outpatient setting of a memory clinic. Frequency and risk factors of post-lumbar puncture headache]. (2007) (26)
Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer’s disease (2019) (26)
Successful Verbal Retrieval in Elderly Subjects Is Related to Concurrent Hippocampal and Posterior Cingulate Activation (2006) (26)
Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and folate, in cerebrospinal fluid (2012) (26)
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
Novelty detection and repetition suppression in a passive picture viewing task: A possible approach for the evaluation of neuropsychiatric disorders (2002) (25)
Impact of coronary heart disease on cognitive decline in Alzheimer's disease: a prospective longitudinal cohort study in primary care. (2017) (25)
Association of amygdala volumes with cortisol secretion in unipolar depressed patients (2012) (25)
A Reduction in Delay Discounting by Using Episodic Future Imagination and the Association with Episodic Memory Capacity (2017) (25)
Human genome–guided identification of memory-modulating drugs (2013) (25)
Left anterior temporal lobe sustains naming in Alzheimer's dementia and mild cognitive impairment. (2011) (25)
Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection (2018) (25)
Mortality in incident dementia – results from the German Study on Aging, Cognition, and Dementia in Primary Care Patients (2015) (24)
Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. (2006) (24)
Response-related fMRI of veridical and false recognition of words (2004) (24)
General practitioners’ views on (long-term) prescription and use of problematic and potentially inappropriate medication for oldest-old patients—A qualitative interview study with GPs (CIM-TRIAD study) (2017) (23)
The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. (2015) (23)
CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume (2018) (22)
Mortality in Individuals with Subjective Cognitive Decline: Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). (2015) (22)
The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD) (2018) (22)
Complex coevolution of depression and health-related quality of life in old age (2015) (22)
Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. (2009) (22)
Genetic Analysis of Association Between Calcium Signaling and Hippocampal Activation, Memory Performance in the Young and Old, and Risk for Sporadic Alzheimer Disease. (2015) (21)
Neuronal correlates of delay discounting in healthy subjects and its implication for addiction: an ALE meta-analysis study (2019) (21)
“Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia” (2019) (21)
Effects of deep brain stimulation on prepulse inhibition in obsessive-compulsive disorder (2015) (21)
Interindividual variation of cerebral activation during encoding and retrieval of words (2000) (21)
Stress and Alzheimer’s disease (2019) (20)
Advance directives and power of attorney for health care in the oldest-old – results of the AgeQualiDe study (2017) (20)
Computational dissection of human episodic memory reveals mental process-specific genetic profiles (2015) (20)
Differential risk of incident Alzheimer's disease dementia in stable versus unstable patterns of subjective cognitive decline (2015) (19)
Gene variations in GSTM3 are a risk factor for Alzheimer's disease (2009) (19)
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 (2021) (19)
Unmet Care Needs in the Oldest Old Primary Care Patients with Cognitive Disorders: Results of the AgeCoDe and AgeQualiDe Study (2017) (19)
Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer’s disease (2020) (19)
Effect of Cardiovascular and Metabolic Disease on Cognitive Test Performance and Cognitive Change in Older Adults (2012) (18)
TBK 1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2019) (18)
Encoding and retrieval related cerebral activation in continuous verbal recognition. (2001) (18)
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study (2020) (18)
Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea (2020) (18)
Identical distribution of the alpha 2-macroglobulin pentanucleotide deletion in subjects with Alzheimer disease and controls in a German population. (2000) (18)
Response-related fMRI analysis during encoding and retrieval revealed differences in cerebral activation by retrieval success (2000) (18)
Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers (2019) (18)
PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease (2006) (18)
Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment (2019) (17)
Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer’s disease: a voxel-based lesion mapping study (2015) (17)
Differences of cerebral activation between superior and inferior learners during motor sequence encoding and retrieval (2004) (17)
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer’s disease (2020) (17)
Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET (2021) (17)
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 (2021) (16)
Incident Subjective Cognitive Decline Does Not Predict Mortality in the Elderly – Results from the Longitudinal German Study on Ageing, Cognition, and Dementia (AgeCoDe) (2016) (16)
One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases (2020) (16)
A microRNA signature that correlates with cognition and is a target against cognitive decline (2021) (16)
[CERAD-NP battery: Age-, gender- and education-specific reference values for selected subtests. Results of the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe)]. (2009) (15)
The MOPEAD project: Advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer's disease in the community (2019) (15)
Association of an interleukin-1beta gene polymorphism at position -511 with Alzheimer's disease. (2003) (15)
2017 NIA-AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER’S DISEASE CONTINUUM (2017) (15)
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. (2022) (15)
Interrelations of Alzheimer´s disease candidate biomarkers neurogranin, fatty acid‐binding protein 3 and ferritin to neurodegeneration and neuroinflammation (2020) (15)
Correlates of hospitalization among the oldest old: results of the AgeCoDe–AgeQualiDe prospective cohort study (2019) (14)
Bupropion for the Treatment of Apathy in Alzheimer Disease (2020) (14)
No association between an intronic biallelic polymorphism of the FE65 gene and Alzheimer's disease. (2000) (14)
Perspective of elderly patients on chronic use of potentially inappropriate medication – Results of the qualitative CIM-TRIAD study (2018) (14)
TREM2 rare variant p.R47H is not associated with Parkinson's disease. (2016) (14)
A simple and fast method for the preparation of n.c.a. 2-[18F]F-A85380 for human use. (2005) (14)
Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease. (2018) (14)
Computer-assisted prediction of clinical progression in the earliest stages of AD (2018) (14)
Association of N-acetylaspartate and cerebrospinal fluid Aβ42 in dementia. (2011) (13)
Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers (2022) (13)
Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy (2021) (13)
Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial (2021) (13)
Risk factors and early signs of Alzheimer's disease in a family study sample. Risk of AD. (2006) (13)
[Services for the early recognition of psychoses and bipolar disorders in Germany: inventory survey study]. (2015) (13)
Alpha-1-Antichymotrypsin Gene Polymorphism and Risk for Sporadic Alzheimer’s Disease in a German Population (1999) (13)
Exploring Genetic Associations of Alzheimer’s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes (2018) (13)
Wishes and preferences for an online lifestyle program for brain health—A mixed methods study (2018) (12)
Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. (2020) (12)
Health Literacy in Individuals at Risk for Alzheimer’s Dementia: A Systematic Review (2019) (12)
APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease. (2013) (12)
Influence of thermal annealing on photoluminescence and structural properties of N,N'-diphenyl-N,N'-bis(1-naphthylphenyl)-1,1'-biphenyl-4,4'-diamine (α-NPD) organic thin films (2007) (12)
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study (2020) (12)
Neurocognitive disorders in ICD‐11: the debate and its outcome (2018) (11)
Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes (2011) (11)
Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer’s disease (2021) (11)
Association of CETP polymorphisms with the risk of vascular dementia and white matter lesions (2009) (11)
Does visual impairment affect social ties in late life? Findings of a multicenter prospective cohort study in Germany (2016) (11)
No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer disease in a German population (1999) (11)
Novel genetic matching methods for handling population stratification in genome-wide association studies (2015) (11)
Gene‐gene interaction between interleukin‐6 and α2‐macroglobulin influences the risk for Alzheimer's disease (2000) (11)
Inter-rater reliability of family history information on psychiatric disorders in relatives (2001) (10)
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (vol 41, pg 1088, 2009) (2013) (10)
Polythetic Diagnostic Approach to the Borderline Personality Disorder (2000) (10)
Eicosapentaenoic Acid Is Associated with Decreased Incidence of Alzheimer’s Dementia in the Oldest Old (2021) (10)
Informal caregivers’ perspectives on health of and (potentially inappropriate) medication for (relatively) independent oldest-old people – a qualitative interview study (2018) (10)
Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer’s disease spectrum (2020) (10)
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers (2022) (10)
Growth and characterization of AlGaN/GaN HEMT on SiCOI substrates (2005) (10)
SUCLG 2 identified as both a determinator of CSF A b 1 – 42 levels and an attenuator of cognitive decline in Alzheimer ’ s disease (2014) (10)
Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate) (2019) (9)
[Report from an ongoing research project: The Cologne Research and Development Network (CoRe-Net) and the value-based approach to healthcare]. (2018) (9)
Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer’s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness (2019) (9)
Quality of health care with regard to detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): study protocol (2019) (9)
Layer Cross-Fading at Organic/Organic Interfaces in OVPD-Processed Red Phosphorescent Organic Light Emitting Diodes as a New Concept to Increase Current and Luminous Efficacy (2009) (9)
Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer’s disease spectrum (2020) (9)
Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis. (2010) (8)
FC2D COGNITIVE AND NEUROBIOLOGICAL RISK INDICATORS IN EARLY AND LATE PRODROMAL STAGES (2006) (8)
Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer’s disease (2006) (8)
Amyloid b peptide ratio 42 / 40 but not A b 42 correlates with phospho-Tau in patients with low-and high-CSF A b 40 load (2007) (8)
Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease (2022) (8)
Prediction of dementia of Alzheimer type by different types of subjective cognitive decline (2020) (8)
Contribution of Apolipoprotein E and Cathepsin D Genotypes to the Familial Aggregation of Alzheimer’s Disease (2004) (7)
[Reliability of multicenter magnetic resonance imaging. Results of a phantom test and in vivo measurements by the German Dementia Competence Network]. (2006) (7)
Treatment of hypersexuality in Parkinson's disease with carbamazepine—A case report (2009) (7)
Framework : Toward a Biological Definition of Alzheimer ' s Disease (2018) (7)
Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction (2022) (7)
[Treating Late Life Depression with Antidepressants--A Summary of Recommendations in International Guidelines]. (2015) (7)
Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT (2019) (7)
A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY (2018) (7)
PLASMA HOMOCYSTEINE AND CEREBROSPINAL FLUID NEURODEGENERATION BIOMARKERS IN MILD COGNITIVE IMPAIRMENT AND DEMENTIA (2009) (7)
18F-PI2620 TAU-PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTI-CENTER EVALUATION (2019) (6)
Characterization of Cerebellar Atrophy and Resting State Functional Connectivity Patterns in Sporadic Adult-Onset Ataxia of Unknown Etiology (SAOA) (2019) (6)
Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. (2021) (6)
18F-PI2620 TAU-PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTI-CENTER EVALUATION (2019) (6)
Refining the understanding of typical Alzheimer disease (2019) (6)
ABNORMAL FUNCTIONAL CONNECTIVITY WITHIN DEFAULT MODE NETWORK IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE: SELF-REFLECTION OF OWN MEMORY DEFICITS? (2016) (6)
Advance directives for future dementia can be modified by a brief video presentation on dementia care: An experimental study (2018) (6)
What are we trying to prevent in Alzheimer disease? (2019) (6)
Introduction of Innovative Dopant Concentration Profiles to Broaden the Recombination Zone of Phosphorescent OVPD-Processed Organic Light Emitting Diodes (2009) (6)
Interaction of two genes possibly involved in the regulation of the amyloid precursor protein (APP) processing (2000) (6)
[Prevention of cognitive decline and dementia by treatment of risk factors]. (2019) (6)
[ICD-11: Neurocognitive Disorders]. (2018) (6)
Not all, but specific types of cognitive complaints predict decline to MCI (2018) (6)
General practitioners’ attitude toward early and pre‐dementia diagnosis of AD in five European countries—A MOPEAD project survey (2021) (6)
No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. (2016) (5)
Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic review (2021) (5)
Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network (2022) (5)
Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease (2022) (5)
Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum. (2021) (5)
Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline (2021) (5)
A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2 (2020) (5)
Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients (2022) (5)
Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. (2022) (5)
A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04) (2011) (5)
[Early detection of Alzheimer's disease and approaches for prevention]. (2019) (4)
Feasibility of Digital Memory Assessments in an Unsupervised and Remote Study Setting (2022) (4)
What are the risk factors for avoidable transitions in the last year of life? A qualitative exploration of professionals’ perspectives for improving care in Germany (2021) (4)
Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review (2020) (4)
Cognitive Complaints in Memory Clinic Patients and in Depressive Patients: An Interpretative Phenomenological Analysis (2019) (4)
IMPAIRED VISUAL FEATURE BINDING IN PATIENTS AT RISK FOR ALZHEIMER'S DISEASE: EVIDENCE FROM PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE (SCD) AND FROM PATIENTS WITH MCI (2014) (4)
Si(111) as alternative substrate for AlGaN/GaN HEMT (2003) (4)
MRI as a Surrogate Marker in Clinical Trials in Alzheimer’s Disease (2009) (4)
Advanced buffers for AlGaN/GaN HEMT and InGaN/GaN MQW on silicon substrates (2006) (4)
Anti-amyloid antibody therapies in Alzheimer's disease. (2023) (4)
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 (2021) (4)
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 (2021) (4)
[Reliability of morbidity data reported by GPs. Results of a longitudinal study in primary care]. (2012) (4)
CNS cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease (2011) (4)
Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study (2022) (4)
Cognitive, Genetic, Brain Volume, and Diffusion Tensor Imaging Markers as Early Indicators of Dementia (2020) (4)
Health literacy in clinical‐high‐risk individuals for psychosis: A systematic mixed‐methods review (2019) (4)
Distribution volume of the nicotinic acetylcholine receptor ligand 2-[F-18]F-A-85380: Nonsmokers versus smokers (2006) (4)
[Evidence-based standards for care of patients with dementia. The interdisciplinary S3 guideline for dementia]. (2010) (3)
ABNORMAL FUNCTIONAL CONNECTIVITY WITHIN DEFAULT MODE NETWORK IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE: SELF-REFLECTION OF OWN MEMORY DEFICITS? (2016) (3)
LATENT-FACTOR STRUCTURE OF THE DELCODE STUDY NEUROPSYCHOLOGICAL TEST BATTERY (2017) (3)
Targeting Lifestyle Behavior to Improve Brain Health: User-Experiences of an Online Program for Individuals with Subjective Cognitive Decline (2020) (3)
[Therapy of psychological and behavioral symptoms in dementia]. (2010) (3)
[Therapy for patients with dementia. Treatment strategies in the elderly]. (2014) (3)
Protective association of HLA‐DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences (2022) (3)
Identification of undiagnosed dementia cases using a web‐based pre‐screening tool: The MOPEAD project (2021) (3)
EXPLAINABLE CONVOLUTIONAL NETWORKS AND MULTIMODAL IMAGING DATA: THE NEXT STEP TOWARDS USING ARTIFICIAL INTELLIGENCE AS DIAGNOSTIC TOOL FOR EARLY DETECTION OF ALZHEIMER'S DISEASE (2019) (3)
Lifelong experiences as a proxy of cognitive reserve moderate the association between connectivity and cognition in Alzheimer's disease (2022) (3)
A Remote Digital Memory Composite to Detect Cognitive Impairment in Memory Clinic Samples in Unsupervised Settings using Mobile Devices (2021) (3)
Biomarker-Based Risk Prediction of Alzheimer's Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects. Study Protocol of the PreDADQoL Project. (2021) (3)
Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly (2020) (3)
[Early detection of Alzheimer's disease and dementia prediction in patients with mild cognitive impairment : Summary of current recommendations]. (2020) (3)
Detection and treatment of mental disorders in patients with coronary heart disease (MenDis-CHD): A cross-sectional study (2020) (3)
[Cognitive Behavioral Therapy and Assertive Community Treatment Reduces Days in Hospital and Delays Hospital Admission in Severe Psychotic Disorders]. (2016) (3)
[Guideline-adherent inpatient psychiatric psychotherapeutic treatment of behavioral and psychological symptoms of dementia : Normative definition of personnel requirements]. (2017) (3)
Subjective memory impairment in healthy elderly specifically predicts decline in episodic memory over 8 years (2013) (3)
Influence of Substrate Temperature on Multilayer Thin Film Growth, Charge Carrier Injection and Efficiency of OVPD-processed Organic Light Emitting Diodes (2008) (3)
Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline (2023) (3)
The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey (2022) (3)
Cholinergic white matter pathways along the Alzheimer's disease continuum (2022) (3)
The role of the right inferior parietal lobule in the calculation of saccade amplitude: An fMRI study (2001) (2)
PROSPECTIVE ASSOCIATIONS BETWEEN VITAMINS, METABOLITES, AND OVERALL DEMENTIA IN THE OLDEST-OLD (2017) (2)
A conceptual framework of subjective cognitive decline (SCD) in preclinical Alzheimer's disease (AD) (2013) (2)
[Clinical Phenomenology of Autoimmune Encephalitis]. (2016) (2)
Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design. (2022) (2)
Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease. (2022) (2)
Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer’s disease: a voxel-based lesion mapping study (2015) (2)
Neural correlates and predictors of subjective cognitive decline in patients with Parkinson’s disease (2021) (2)
European consensus for the diagnosis of MCI and mild dementia: Preparatory phase. (2022) (2)
Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial (2022) (2)
[Advance directive of probands in pharmaceutical research : A medical ethics discussion]. (2018) (2)
Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults (2022) (2)
[Novel neuroimaging perspectives in the diagnosis of dementia]. (2008) (2)
Depression im Alter – Diagnostik, Pathophysiologie und therapeutische Strategien (2018) (2)
One step towards dementia prevention (2018) (2)
EXPECTATIONS OF PATIENTS WITH MCI AND THEIR CAREGIVERS TOWARD PREDICTIVE DIAGNOSIS OF AD: A QUALITATIVE APPROACH (2017) (2)
Functional characterization of a novel TREM2 coding variant linked to familial Alzheimer’s disease (2015) (2)
Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk. (2015) (2)
Complementary pre‐screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project (2021) (2)
WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER’S DISEASE, AND NEURAL NETWORKS (2017) (2)
Rare Variant Testing of Imputed Data: An Analysis Pipeline Typified (2014) (2)
Correction: Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease (2011) (2)
Cognitive reserve moderates the functional connectivity changes in resting-state (2021) (2)
A One-Degree-of-Freedom Test for Supra-Multiplicativity of SNP Effects (2013) (2)
CSF beta-amyloid 42, CSF tau, hippocampal volume and verbal episodic memory performance in early versus late mild cognitive impairment (2013) (1)
Decreased cortical thickness in individuals with subjective cognitive decline with and without CSF‐AD‐pathology: Data from the DELCODE Study (2020) (1)
Impaired self-awareness of cognitive deficits in Parkinson's disease relates to cingulate cortex dysfunction (2021) (1)
USEFULNESS AND STABILITY OF MULTICENTER DIFFUSION TENSOR IMAGING AS AN EARLY MARKER FOR SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: FIRST RESULTS FROM THE PROSPECTIVE DZNE DELCODE STUDY (2017) (1)
DISENTANGLING THE TEMPORAL SEQUENCE OF SUBJECTIVE COGNITIVE DECLINE, DEPRESSIVE SYMPTOMS AND MEMORY DETERIORATION: A TRIVARIATE LATENT DIFFERENCE SCORE ANALYSIS (2019) (1)
Plasma 24S-hydroxycholesterol (cerebrosterol): An indicator of neuronal degeneration and potential state marker for dementia (2000) (1)
The effect of a mindfulness‐based versus health self‐management intervention on cognitive performance in older adults with subjective cognitive decline (SCD): The SCD‐Well randomized controlled trial (2021) (1)
Convergent abnormalities of Î²-amyloid deposition, glucose metabolism, and fMRI activity in the dorsal precuneus in subjective cognitive decline (2021) (1)
Basal forebrain atrophy along the Alzheimer’s disease spectrum and its relevance for subjective cognitive decline (2020) (1)
Low Serum Vitamin D Status Is Associated with Incident Alzheimer’s Dementia in the Oldest Old (2022) (1)
LEVELS OF THE ASTROCYTE-DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER’S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES (2018) (1)
SUBJECTIVE COGNITIVE DECLINE AND PROGRESSION TO DEMENTIA DUE TO AD AND NON-AD IN MEMORY CLINIC AND COMMUNITY-BASED COHORTS (2016) (1)
Harmonisation and Between-Country Differences of the Lifetime of Experiences Questionnaire in Older Adults (2021) (1)
Attention in subjective cognitive decline – Authors' reply (2020) (1)
Histologically confirmed amyloid deposition and low CSF Aβ42 in a cognitively normal subject (2007) (1)
Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults (2021) (1)
Evidence for neuronal compensation during episodic memory in subjective memory impairment (2011) (1)
PET-Imaging of a4ß2* nicotinic acetylcholine receptors in the central and peripheral nervous system (2006) (1)
Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments (2021) (1)
[Memory Clinics in Germany - Results of a Hospital Survey]. (2019) (1)
Musical Activity During Life Is Associated With Multi-Domain Cognitive and Brain Benefits in Older Adults (2022) (1)
Polymorphism in ABCA 1 influences CSF 24 S-hydroxycholesterol levels but is not a major risk factor of Alzheimer ' s disease (1)
An application of electronic nose technology for diagnosis of Alzheimer's disease (2013) (1)
LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER’S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT (2017) (1)
[Memory clinics in Germany-structural requirements and areas of responsibility]. (2020) (1)
Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status (2021) (1)
Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimer’s Disease Dementia via Lead-Lag Analysis (2020) (1)
A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer’s Disease: Results from the MOPEAD Project (2021) (1)
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia (2017) (1)
IMPACT OF NON-PHARMACOLOGIC INTERVENTIONS ON COGNITIVE, BEHAVIORAL, AND EMOTIONAL FUNCTIONING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE: A SYSTEMATIC REVIEW OF CONTROLLED TRIALS (2016) (1)
[The importance of molecular imaging (PET) in the diagnostics of dementia]. (2018) (1)
T40. Alzheimer’s Disease DNA (Hydroxy)Methylome in the Brain and Blood: Evidence for OXT Methylation as a Preclinical Marker (2019) (1)
The IMI‐EU H2020 project MOPEAD: Outcome of different screening methods to identify MCI/early AD (2020) (1)
[Comment on the S3 guidelines Dementia by the DGPPN and the DGN from the psychiatric point of view]. (2010) (1)
CCL17-deficiency alters myeloid cell-responses and prevents cognitive decline in APP/PS1-mice (2015) (1)
Arterial Spin Labeling in Dementia (2010) (1)
Feasibility of mobile app‐based assessment of memory functions: Insights from a citizen science study (2020) (1)
STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY (2018) (1)
Social Cognition in Patients with Amnestic Mild Cognitive Impairment and Mild Dementia of the Alzheimer Type. (2021) (1)
Performance evaluation of automated white matter hyperintensity segmentation algorithms in a multicenter cohort on cognitive impairment and dementia (2023) (1)
Performance of different research criteria and cognitive tests to predict incident Alzheimer’s disease (2013) (1)
MR-Spectroscopy in Dementia (2010) (1)
Measurement and Modeling of Hole Transport in Blends of N,N'-diphenyl-N,N'-bis(1-naphthyl)-1,1'-biphenyl-4,4'-diamine (NPB) and the Hole-conducting Material HIM (2008) (1)
Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea (2020) (1)
[Pharmacological prevention of cognitive decline and dementia]. (2020) (1)
Amyloid-related changes of basal forebrain volume and precuneus functional connectivity in Subjective Cognitive Decline patients (2020) (1)
Big Five, self-reported depression, and anxiety are predictive for Alzheimer's disease (2022) (1)
Quantitative amyloid PET in the AMYPAD diagnostic and patient management study (2021) (1)
The Promotion of Health Literacy (2023) (1)
Multidomain cognitive impairment in non-hospitalized patients with the post-COVID-19 syndrome: results from a prospective monocentric cohort (2022) (1)
A Comparison of Operational Definitions for Mild Cognitive Impairment (2022) (1)
Disentangling the relationship of subjective cognitive decline and depressive symptoms in the development of cognitive decline and dementia. (2022) (1)
Dementia prevention in memory clinics: recommendations from the European task force for brain health services (2023) (1)
Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study (2023) (1)
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 (2021) (1)
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 (2021) (1)
Demands on Health Information and Clinical Practice Guidelines for Patients from the Perspective of Adults with Mental Illness and Family Members: A Qualitative Study with In-Depth Interviews (2022) (1)
Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties (2023) (1)
What Matters to Patients with Alzheimer’s Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions (2022) (1)
The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact (2023) (1)
Combination Therapy for Alzheimer’s Disease — The Next Step (2019) (1)
Structural and Functional Magnetic Resonance Imaging: Mild Cognitive Impairment and Alzheimer Disease. (2013) (1)
[Mild neurocognitive disorder - a disease? For]. (2014) (1)
P3-075 Hippocampal volume reduction in elderly individuals with subjective memory impairment (2004) (1)
Linking early-life bilingualism and cognitive advantage in older adulthood (2022) (0)
THE ASSOCIATION OF AD PATHOLOGY WITH NEUROPSYCHIATRIC SYMPTOMS AND WORRY IN SUBJECTIVE COGNITIVE DECLINE - DATA FROM THE DELCODE STUDY (2019) (0)
Apathy in patients with Alzheimer's disease is a cost-driving factor. (2023) (0)
ANOSOGNOSIA AND CSF-BIOMARKERS IN NONDEMENTED OLDER ADULTS: RESULTS FROM THE DELCODE-STUDY (2019) (0)
EP 17. Preserved frontoparietal brain morphology correlates with beneficial response to deep brain stimulation of the Nucleus basalis of Meynert in patients with Alzheimer’s disease (2016) (0)
OBJECT AND SCENE MEMORY ARE DIFFERENTIALLY ASSOCIATED WITH CSF MARKERS OF ALZHEIMER’S DISEASE AND MRI VOLUMETRY (2017) (0)
Contents of volume 253 (2003) (2003) (0)
Proton MR spectroscopy of the hippocampus at 3 Tesla in patients with major depression under pharmacological treatment (2008) (0)
Homocysteine metabolism and CSF markers for Alzheimer's disease (2009) (0)
OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES (2018) (0)
Steps towards the implementation of amyloid‐PET in memory clinics: AMYPAD Diagnostic and Patient Management Study (2022) (0)
FC02.05 Association of a cathepsin D gene polymorphism with Alzheimer's disease (2000) (0)
ASSOCIATION BETWEEN NEURAL NOVELTY RESPONSES AND CSF BIOMARKERS OF ALZHEIMER’S DISEASE: ANATOMICAL SPECIFICITY AND DEPENDENCE ON ATROPHY (2018) (0)
Individualized MR‐based prediction of cognitive performance in subjects at risk of dementia (2021) (0)
MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT (2017) (0)
Gender differences in the perception of subjective vs. objective cognitive decline: Baseline data from the SCD‐Well Trial (2020) (0)
APOE-ε4 MODULATES LEVELS OF OMEGA-3 AND OMEGA-6 FATTY ACIDS IN ALZHEIMER’S DISEASE DEMENTIA (2018) (0)
P1-252: A multicenter 1H-MRS study of the medial temporal lobe in Alzheimer's disease and mild cognitive impairment (2008) (0)
Exploring the ATN classification system using brain morphology (2021) (0)
Cerebral perfusion changes in untreated schizophrenic patients: A CASL-study at 3 Tesla (2006) (0)
Year : 2011 A genome-wide survey of human short-term memory (2010) (0)
Tau plasma levels in subjective cognitive decline: Results from the DELCODE study (2017) (0)
PATTERNS OF INCREASED AND DECREASED PRECUNEUS FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS (2019) (0)
Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people (66 year-olds) in South Korea (2019) (0)
Predictors of preclinical Alzheimer’s disease in persons with subjective cognitive decline (2020) (0)
Awareness of cognitive decline and CSF‐biomarkers in memory clinic patients: Results from the DELCODE‐study (2020) (0)
Difference in Amyloid Load Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Study from the SILCODE. (2021) (0)
Pre‐screening models for patient engagement: The MOPEAD project (2020) (0)
SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH CSF AMYLOID B 1-42, DEPRESSIVE SYMPTOMS AND EPISODIC MEMORY PERFORMANCE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (2014) (0)
LEVEL OF BRAIN RESERVE ASSOCIATED WITH SPATIAL EXTENT OF TAU-NEURODEGENERATION PATTERN IN ALZHEIMER’S DISEASE (2018) (0)
FDG-PET and Structural MRI in Subjective Memory Impairment (2009) (0)
EVIDENCE FOR AMYLOID PATHOLOGY IN SCD-DATA FROM THE DELCODE STUDY (2017) (0)
P02.255 The relationship between alzheimer's disease, early onset and late-onset depression in the elderly assessed in a family study (2000) (0)
Regional 1H-MR-spectroscopy with respect to the theoretical distribution of neuropathology in AD patients (2000) (0)
INTERPRETATIVE PHENOMENOLOGICAL ANALYSIS OF COGNITIVE COMPLAINTS REVEALS COMMONALITIES AND DIFFERENCES BETWEEN MEMORY-CLINIC PATIENTS, DEPRESSIVE PATIENTS, AND HEALTHY ELDERLY (2017) (0)
Association of acetylcholinesterase inhibitor and memantine treatment with cognitive function in patients with clinical dementia syndrome with and without post‐mortem Alzheimer pathology (2022) (0)
Evaluation of the efficacy and safety of orally administered BI425809 during a 12‐week treatment period compared with placebo in patients with cognitive impairment due to Alzheimer’s disease (2020) (0)
The use of amyloid‐PET in memory clinic patients: AMYPAD Diagnostic and Patient Management Study (2022) (0)
Cognitive Behavioral Therapy for Late-Life Depression (CBTlate): Results of a Multicenter, Randomized, Observer-Blinded, Controlled Trial. (2023) (0)
Power values a of SMT under 3-SNP-recessive models. (2013) (0)
Hippocampal volumetric variability is associated with memory in subjective cognitive decline (2020) (0)
The relationship of CSF biomarker of tau to in vivo tau pathology is mediated by amyloid levels in AD patients (2017) (0)
SUBJECTIVE COGNITIVE DECLINE VERSUS SUBTLE DEFICITS AS INDICATORS OF PRECLINICAL AD: RESULTS FROM THE MULTICENTER OBSERVATIONAL STUDY ON PREDEMENTIA ALZHEIMER’S DISEASE (DELCODE) STUDY (2019) (0)
A cost‐consequence analysis of early detection of AD in the MOPEAD project — A project within the EU research agenda IMI‐2 (2020) (0)
COUNSELING AND DISCLOSURE IN RISK PREDICTION OF ALZHEIMER’S DEMENTIA: IMPACT ON MCI PATIENTS AND THEIR CAREGIVERS—THE PREDADQOL STUDY (2018) (0)
THE SCD-WELL RANDOMIZED CONTROLLED TRIAL: EFFECTS OF A MINDFULNESS-BASED INTERVENTION VERSUS HEALTH EDUCATION ON MENTAL HEALTH AND COGNITION IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE (2019) (0)
ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT RISK STAGES OF ALZHEIMER’S DEMENTIA (2019) (0)
CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLEUS BASALIS MEYNERT IN AMYLOID-POSITIVE SCD (2019) (0)
The psychological consequences of living with coronary heart disease: Are patients' psychological needs served? A mixed‐method study in Germany (2022) (0)
Effect of Neuroinflammation on white matter structure and memory performance in the spectrum from aging to AD (2022) (0)
Investigating brain structure in different FTLD subtypes using voxel-based morphometry – Data from the multicentric FTLD consortium’s study Germany (2014) (0)
EICOSAPENTAENOIC ACID BUT NOT DOCOSAHEXAENOIC ACID IS ASSOCIATED WITH ALZHEIMER’S DISEASE RISK IN THE OLDEST-OLD (2018) (0)
THE AMYPAD-DX CONTROLLED TRIAL ON THE DIAGNOSTIC VALUE OF AMYLOID PET (2017) (0)
A Cognitive Reserve Network That Moderates the Relationship Between Alzheimer’s Disease Pathology and Cognition (2022) (0)
Using neuropsychological criteria to distinguish between memory clinic patients with subjective cognitive decline and MCI (2015) (0)
OPTIMAL HARMONIZATION OF COGNITIVE MEASURES ENHANCES THE DETECTION OF GENETIC EFFECTS ON ALZHEIMER’S DISEASE PROGRESSION: A COMPARISON OF SIX STATISTICAL APPROACHES IN 1796 MCI PATIENTS FROM THREE COHORTS (2017) (0)
Compounds in exhaled air for the detection of Alzheimer's disease (2013) (0)
CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSF-TAU ON MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER’S DISEASE (2017) (0)
RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, β-AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE) (2018) (0)
MODELS OF PATIENT ENGAGEMENT IN ALZHEIMER’S DISEASE (MOPEAD): A EUROPEAN MULTINATIONAL PROJECT TO DEVELOP AND TEST INNOVATIVE PATIENT ENGAGEMENT STRATEGIES (2018) (0)
Neural mechanisms of subjective memory impairment (2009) (0)
Comparison of Patient and Proxy Assessment of Patient-Centeredness in the Care of Coronary Heart Disease: A Cross Sectional Survey Using the PACIC-S11.1 (2020) (0)
In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study (2021) (0)
CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLEUS BASALIS MEYNERT IN AMYLOID-POSITIVE SCD (2019) (0)
PREVALENCE OF PRECLINICAL ALZHEIMER’S DISEASE IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE: COMPARISON OF THREE EUROPEAN MEMORY CLINIC SAMPLES (2016) (0)
Interindividual variability of cerebral activation in a verbal memory paradigm (2000) (0)
Midlife occupational cognitive requirements protect cognitive function in old age by increasing cognitive reserve (2022) (0)
Algorithmic Fairness in Biomarker‐Based Machine Learning Models to Predict Alzheimer’s Dementia in Individuals with Mild Cognitive Impairment (2022) (0)
Frontal activation is related to retrieval effort in a continuous recognition paradigm (2000) (0)
F167. ACCESS, UNDERSTAND, APPRAISE AND APPLY TO / OF HEALTH INFORMATION AND HEALTH LITERACY IN INDIVIDUALS AT-RISK FOR PSYCHOSIS: A SYSTEMATIC REVIEW (2018) (0)
Distribution volume of the nicotinic acetylcholine receptor ligand 2-[F-18]F-A-85380 studied in smokers and non-smokers (2006) (0)
APPLICATION OF THE ‘A/T/N’ BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS (2017) (0)
A residual marker of cognitive reserve is associated with resting-state intrinsic functional connectivity along the Alzheimer's disease continuum (2022) (0)
IN VIVO TAUOPATHY MEASURED WITH [18F]-AV-1451 IS DIFFERENTIALLY RELATED TO CSF BIOMARKERS OF TAU IN ALZHEIMER’S DISEASE: THE INFLUENCE OF AMYLOID DEPOSITION (2017) (0)
Prediction of Alzheimer dementia – current state (2013) (0)
THE PHENOMENOLOGY AND THE NEURONAL CORRELATES OF EPISODIC FUTURE IMAGINATION IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE AND HEALTHY CONTROLS (2017) (0)
USING NEUROMELANIN-SENSITIVE MRI TO CHARACTERISE THE STRUCTURAL INTEGRITY OF THE HUMAN LOCUS COERULEUS AT DIFFERENT STAGES OF ALZHEIMER’S DISEASE (2017) (0)
Support vector machine classification enables detection of primary progressive aphasia subtypes with MRI (2015) (0)
Subjective memory impairment – A 18F-FDG PET cross-sectional case-control study (2006) (0)
Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project (2019) (0)
The last year of life for patients dying from cancer vs. non-cancer causes: a retrospective cross-sectional survey of bereaved relatives (2022) (0)
QUALITY ASSURANCE IN DELCODE: A MULTI-CENTER NEUROIMAGING STUDY (2017) (0)
Papassotiropoulos 2010 MolPsychiat Supplementary (2014) (0)
Smoking upregulates a4ß2* nicotinic acetylcholine receptors in brainstem and cerebellum (2006) (0)
Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants (2020) (0)
Novel genetic matching methods for handling population stratification in genome-wide association studies (2015) (0)
RISK KNOWLEDGE OF MCI PATIENTS IN PREDICTIVE DIAGNOSIS OF ALZHEIMER’S DEMENTIA: PRELIMINARY DATA OF A MIXED METHOD APPROACH—THE PREDADQOL STUDY (2018) (0)
Neuroanatomical correlates of the behavioral and psychiatric symptoms in Alzheimer's disease: A voxel-based morphometry study (2013) (0)
ASSESSMENT OF SOCIAL COGNITIVE ABILITIES IN PATIENTS WITH MCI AND MILD AD COMPARED TO YOUNGER AND OLDER HEALTHY CONTROLS (2018) (0)
Smoking upregulates α4ß2* nicotinic acetylcholine receptors in brainstem and cerebellum (2006) (0)
Individualized Gaussian Process-based Prediction of Memory Performance and Biomarker Status in Ageing and Alzheimer’s disease (2022) (0)
HIPPOCAMPAL GREY MATTER ATROPHY IS ASSOCIATED WITH THE FREE AND CUED SELECTIVE REMINDING TEST (2014) (0)
The clinical use of Alzheimer’s biomarkers in patients with mild cognitive impairment (2021) (0)
P3-001 Alterations of peripheral cholesterol metabolites, 24S- and 27-hydroxycholesterol in demented patients (2004) (0)
Prediction of amyloid‐positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize number‐needed‐to‐screen (2021) (0)
CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSF-TAU ON MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER’S DISEASE (2017) (0)
IC-P-038 FDG PET in subjective memory impairment (2006) (0)
Neuroanatomical correlates of the behavioral and psychiatric symptoms in Alzheimer's disease: A voxel-based morphometry study (2013) (0)
Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients (2021) (0)
ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT RISK STAGES OF ALZHEIMER’S DEMENTIA (2019) (0)
MICROSTRUCTURAL CHANGES IN ALZHEIMER’S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA (2018) (0)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
Detection of Neural Compensation at the Pre-Dementia State (2010) (0)
DELAY DISCOUNTING IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE, ELDERLY CONTROLS, AND YOUNG CONTROLS (2014) (0)
TBK1 loss-of function and dominant-negative mutations in an extended European cohort of FTD and ALS patients (2016) (0)
Subject Index Vol. 7, 2010 (2010) (0)
Association of domain‐specific cognitive functions with regional pattern of atrophy and functional connectivity across the Alzheimer’s disease spectrum: An analysis from the DELCODE cohort (2020) (0)
Front & Back Matter (2012) (0)
P2-153: Alterations of brain cholesterol metabolism: Relevance of desmosterol in Alzheimer’s disease and vascular dementia (2006) (0)
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6 (2021) (0)
SUBJECTIVE AND VERY FIRST OBJECTIVE COGNITIVE DECLINE (2018) (0)
AMYPAD-DPMS PRELIMINARY RESULTS: PARTICIPANTS’ BASELINE FEATURES (2019) (0)
Correlation of CSF biomarkers with 1H-MRS metabolites of the medial temporal lobe in Alzheimer's Disease (2009) (0)
P3-122 APOE-ε4 MODULATES LEVELS OF OMEGA-3 AND OMEGA-6 FATTYACIDS IN ALZHEIMER’S DISEASE DEMENTIA (2018) (0)
EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS (2018) (0)
Featured Article Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease (2014) (0)
FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE Cγ2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER’S DISEASE (2017) (0)
First results of the AMYPAD Prognostic and Natural History Study: amyloid‐PET Centiloid predicts cognitive functioning in a pre‐dementia population (2022) (0)
Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study (2020) (0)
SOCIAL COGNITION IN PATIENTS WITH MCI AND MILD AD (2019) (0)
P4‐272: Withdrawn (2015) (0)
Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
"MOVE ON UP": THE MOBI ASSIST-PROGRAMME (2018) (0)
Cortical thinning in subjective memory impairment (2013) (0)
TREM2 is not associated with accelerated decline of the mini mental status examination in late onset Alzheimer's disease (2015) (0)
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease (2018) (0)
Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo-controlled multi-center study (2011) (0)
INSPIRATION: Study design and preliminary results of a crosssectional risk AD‐profiling study (2021) (0)
6 .Diagnostische Methoden (2018) (0)
Featured Research Sessions: F5-01: Subjective Cognitive Decline in Preclinical Alzheimer’s Disease P824 FEATURED RESEARCH SESSIONS: F5-01: SUBJECTIVE COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE F5-01-01 A CONCEPTUAL FRAMEWORK OF SUBJECTIVE COGNITIVE DECLINE (SCD) IN PRECLINICAL ALZHEIMER’S (2013) (0)
Cortical thinning in subjective memory impairment (2013) (0)
Lifestyle differences modulate the effects of cognitive reserve on functional connectivity (2020) (0)
Neuroimaging in Dementia (2011) (0)
Prognostic value of plasma Amyloid‐β 42/40 ratio in early and pre‐clinical AD (2022) (0)
In vivo locus coeruleus imaging in Alzheimer’s and Parkinson’s disease (2020) (0)
A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients (2015) (0)
Reduced delay discounting through episodic future imagination in healthy old subjects but not in subjects with subjective cognitive decline: An fMRI study (2015) (0)
CSF biomarkers and disease progression in an interrupted MCI trial (2012) (0)
RELATIONSHIP BETWEEN GLOBAL CONNECTIVITY, AMYLOID AND TAU IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER’S DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT (2019) (0)
Contents Vol. 78, 2014 (2015) (0)
The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers (2020) (0)
Anosognosia in Alzheimer’s disease associated with tau accumulation and hypometabolism in frontal areas (2020) (0)
RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER’S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE? (2018) (0)
Genome-wide association study using cerebrospinal fluid biomarkers beta-amyloid-42 and pTau181 in German samples of Alzheimer's disease (2012) (0)
1H-MRS IN SUBJECTS WITH SCD, MCI AND AD (2016) (0)
ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER’S DISEASE BASED ON MULTICENTER RESTING-STATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY (2017) (0)
Activation of Anterior Cingulate Gyrus, Right Medial Frontal Gyrus, and Parietal Visual Association Cortex during Retrieval: An Event-related Functional MRI-Analysis (1998) (0)
Cerebrospinal fluid L-arginine and symmetrical dimethylarginine are associated with increased soluble amyloid precursor protein beta production in Alzheimer's disease (2012) (0)
Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study (2019) (0)
P2-283 FDG-PET in subjective memory impairment (2006) (0)
Classifying primary progressive aphasias individually with support vector machine approaches in MRI data (2016) (0)
IC-P-155 STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENTAND ALZHEIMER’S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROMTHEDELCODE STUDY (2018) (0)
Association between SCD‐Plus features and GDS factors in subjective cognitive decline and healthy controls in the studies DELCODE and SILCODE (2021) (0)
Impact of the disclosure of amyloid‐PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS) (2020) (0)
IC-P-066 A multicenter 1H-MRS study of the medial temporal lobe in MCI and dementia (2006) (0)
Substantia nigra integrity is associated with poorer recognition memory for novel stimuli in early Alzheimer’s disease (2022) (0)
First results of the AMYPAD Prognostic and Natural History Study: amyloid‐PET centiloids predicts cognitive functioning in a pre‐dementia population (2022) (0)
Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to AD among subjects with mild cognitive impairment (2016) (0)
THE PHENOMENOLOGY AND THE NEURONAL CORRELATES OF EPISODIC FUTURE IMAGINATION IN PERSONS WITH SUBJECTIVE COGNITIVE DECLINE AND HEALTHY CONTROLS (2017) (0)
CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY (2018) (0)
A high fMRI activation deviation score is linked to worse clinical phenotype and Aß42/40 positivity. (2020) (0)
STATUS QUO OF HEALTH LITERACY IN INDIVIDUALS AT RISK FOR DEVELOPING ALZHEIMER'S DISEASE: FIRST DATA OF A SYSTEMATIC REVIEW (2018) (0)
Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples (2019) (0)
Cost of illness of apathy in Alzheimer’s disease (2021) (0)
[Brain health services: individual dementia risk profiling at the Cologne Alzheimer Prevention Center]. (2023) (0)
Editorial: Exploring Reliable Markers and Prediction Indexes for the Progression From Subjective Cognitive Decline to Cognitive Impairment (2021) (0)
Early-Phase F-18-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neurodegeneration (2019) (0)
Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease (2010) (0)
1H-MRS IN SUBJECTS WITH SCD, MCI AND ALZHEIMER'S DISEASE (2016) (0)
P2-342 A multicenter 1H-MRS study of the medial temporal lobe in MCI and dementia (2006) (0)
DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (2018) (0)
Correction to: Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review (2022) (0)
F1-04-03 EFFECTS OFAGE AND TAUMEASURED IN CSF ONMNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS (2018) (0)
Study on Organic Triplet Exciton Emission and Quenching Processes by Low-temperature Photo- and Electroluminescence Spectroscopy (2008) (0)
HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EURO-SCD STUDY (2018) (0)
Violet-to-red photoluminescence of spiro-TAD organic films doped with different organic dyes (2007) (0)
PREDICTING FUTURE DEMENTIA USING COGNITION, APOE, AND STRUCTURAL MAGNETIC RESONANCE IMAGING: THE ROLE OF WHITE MATTER INTEGRITY (2019) (0)
Application of Developed APCVD Transparent Conducting Oxides and Undercoat Technologies for Economical OLED Lighting (2011) (0)
P3-159 Role of glutathione S-transferase omega gene polymorphisms in Alzheimer's disease, vascular dementia and stroke (2004) (0)
Dispositif électroluminescent organique avec injection ajustable de porteur de charge (2008) (0)
Risk for dementia in subjective memory impairment, early mild cognitive impairment and late mild cognitive impairment (2012) (0)
Underlying clusters of NIA‐AA Research Framework stage 2 criteria and their relationship with AD biomarkers in the DELCODE study (2022) (0)
[Late life depression - Diagnosis, pathophysiology and therapeutic strategies]. (2018) (0)
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE) (2018) (0)
Rare missense variant (R251G) on APOE counterbalances the Alzheimer’s disease risk associated with APOE‐ε4 (2022) (0)
SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS (2018) (0)
INSPIRATION: results of a cross‐sectional AD risk‐profiling study (2022) (0)
General practitioners’ opinion on early and pre‐dementia diagnosis of AD: A MOPEAD project survey in five European countries (2020) (0)
Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease (2018) (0)
MICROSTRUCTURAL CHANGES IN ALZHEIMER’S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA (2018) (0)
Correction to: Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review (2022) (0)
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study (2020) (0)
Soluble TAM receptor biomarkers: Neuroprotection in AD neuroinflammation?" (2022) (0)
Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts. (2023) (0)
Self‐reflection is associated with markers of Alzheimer’s disease in cognitively unimpaired older adults (2021) (0)
A PHASE II STUDY EVALUATING EFFICACY, SAFETY, AND TOLERABILITY OF ORAL BI 425809 IN PATIENTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE DEMENTIA (2019) (0)
Using a virtual reality path integration task to investigate entorhinal functioning in individuals with and without subjective cognitive decline (2021) (0)
An automated, geometry-based method for the analysis of hippocampal thickness (2023) (0)
Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity. (2016) (0)
Speed of cognitive decline in biomarker stratified SCD subgroups (2022) (0)
Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review (2022) (0)
VASCULAR DEMENTIA AND DIETARY PATTERN: A SUBPOPULATION ANALYSIS OF THE ADVENTIST HEALTH STUDY-2 (2018) (0)
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease (2020) (0)
Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trial (2022) (0)
Performance comparison of automated white matter lesion segmentation algorithms in the DELCODE Study (2020) (0)
Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial (2023) (0)
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer’s disease (2021) (0)
Automated segmentation of the locus coeruleus in aging and Alzheimer’s disease using 3T neuromelanin‐sensitive MRI (2021) (0)
Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial (2022) (0)
The latent dementia phenotype δ is associated with the CSF Alzheimer's disease biomarker signature in subjects with mild cognitive impairment (2015) (0)
Predementia Counseling (2023) (0)
MINOR NEUROPSYCHOLOGICAL DEFICITS IN COGNITIVELY NORMAL OLDER INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: RESULTS FROM THE DELCODE STUDY (2019) (0)
Alzheimerʼs Disease biomarkers and cortical thickness in persons reporting subjective cognitive decline and healthy controls: Data derived from the DZNE DELCDODE-Study (2020) (0)
Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers (2019) (0)
NEUROPSYCHIATRIC SYMPTOMS IN AT-RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY (2018) (0)
Influence of MR system, field strength and automatic planning routines on Voxel Based Morphometry (VBM) (2008) (0)
Altered resting state activity associated with anosognosia in Alzheimer's clinical syndrome: Findings from the DELCODE study (2020) (0)
1 NIAAA Research Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 11-2 7-17 3 4 (2017) (0)
EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS (2018) (0)
Reliability of DTI: A european multicenter study (2010) (0)
PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM (2017) (0)
IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE (2017) (0)
MEMORY IMPAIRMENTAND RISK OF ALZHEIMER’S DEMENTIA IN PEOPLE WITH MCI (2013) (0)
Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimer’s disease: The first step towards comprehensive artificial intelligence (2021) (0)
P4-084 GENOME-WIDE ASSOCIATION STUDY USING CEREBROSPINAL FLUID BIOMARKERS BETA- AMYLOID-42 AND PTAU181 IN GERMAN SAMPLES OFALZHEIMER’S DISEASE (2012) (0)
YRP.09 Activation differences in sufficient and insufficient learning – an fMRI study of procedural motor learning (2002) (0)
Face-name associative recognition is impaired in patients with subjective cognitive decline (2015) (0)
EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS (2018) (0)
Two progression patterns in Alzheimer's disease identified from structural MRI in a memory clinic‐based cohort (2022) (0)
BUPROPION FOR THE TREATMENT OF APATHY IN ALZHEIMER’S DISEASE: A MULTICENTER RANDOMIZED CONTROLLED TRIAL (2019) (0)
[An unacceptable study]. (2016) (0)
IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE (2017) (0)
1 In vivo MRI assessment of the human Locus Coeruleus along its rostrocaudal extent in young and older adults (2018) (0)
P3-069 Reliability of multicenter MRI. Results of a phantom test and in vivo MRI measurement (2004) (0)
MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER’S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY (2018) (0)
Age-related functional changes in domain-speci ﬁ c medial temporal lobe pathways Neurobiology of Aging (2018) (0)
Subjective memory concerns, objective memory impairment and risk of Alzheimer's dementia in people with MCI (2013) (0)
IC-P2-141: Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease: A longitudinal study (2008) (0)
P.0095 Outcome Associated with Suicidality in Inpatients with Symptoms of depression (OASIS-D): Design of a study assessing usual care outcomes (2021) (0)
Altered resting state activity associatedwith anosognosia in Alzheimer’s clinical syndrome: Findings from theDELCODE study (2020) (0)
Alzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood (2019) (0)
Subject Index Vol. 10, 1999 (1999) (0)
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2 (2023) (0)
Voxel-based morphometry in primary progressive aphasia and its subtypes–data from the multicentric FTLD consortium’s study Germany (2014) (0)
FREQUENCY OF SUBJECTIVE COGNITIVE DECLINE CRITERIA IN STAGE 2 OF THE NEW NIA-AA FRAMEWORK: A MULTI-COHORT STUDY FROM THE SUBJECTIVE COGNITIVE DECLINE PROFESSIONAL INTEREST AREA (2019) (0)
Correction: A One-Degree-of-Freedom Test for Supra-Multiplicativity of SNP Effects (2014) (0)
Characterization of the NIA‐AA Research Framework stage 2 in the longitudinal multicenter DELCODE study (2021) (0)
RELATIONSHIP BETWEEN LOCUS COERULEUS MRI CONTRAST, COGNITION AND CSF BIOMARKERS IN AGING AND ALZHEIMER’S DISEASE (2018) (0)
Reduced delay discounting through episodic future imagination in healthy old subjects but not in subjects with subjective cognitive decline: An fMRI study (2015) (0)
THE ROLE OF SUBJECTIVE COGNITIVE CONCERN IN AGING (2017) (0)
A 6-items Questionnaire (6-QMD) captures a Mediterranean like dietary pattern and is associated with memory performance and hippocampal volume in elderly and persons at risk for Alzheimer’s disease (2023) (0)
DOMAIN-SPECIFIC MNEMONIC DISCRIMINATION IN AGEING AND EARLY STAGES OF ALZHEIMER’S DISEASE (2017) (0)
‘HEALTHY DIET' AND COGNITIVE STATUS IN THE OLDEST OLD (2016) (0)
CORTICAL THICKNESS AND ALZHEIMER’S RELATED BIOMARKERS IN SUBJECTIVE COGNITIVE DECLINE - DATA FROM THE DELCODE-STUDY (2019) (0)
Editorial: Lecanemab: Appropriate Use Recommendations – A Commentary from a European Perspective (2023) (0)
Evaluation of evidence grades in psychiatry and psychotherapy guidelines (2020) (0)
HIPPOCAMPAL INTRINSIC CONNECTIVITY SUPPORTS COGNITIVE RESERVE IN AMYLOID-POSITIVE COGNITIVELY NORMAL SUBJECTS AND ALZHEIMER’S DISEASE PATIENTS (2019) (0)
HIPPOCAMPAL GREY MATTER ATROPHY IS ASSOCIATED WITH THE FREE AND CUED SELECTIVE REMINDING TEST (2014) (0)
P-129 Cognitive performance and grey matter structure in elderly with subjective memory impairment (2007) (0)
FACE NAME ASSOCIATIVE RECOGNITION IS ASSOCIATED WITH ALZHEIMER’S DISEASE BIOMARKERS IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE (2016) (0)
[A contribution to the current discussion on anti-dementia drugs in Germany]. (2007) (0)
Evaluation of the efficacy and safety of orally administered BI425809 during a 12â•’week treatment period compared with placebo in patients with cognitive impairment due to Alzheimerâ•Žs disease: Human: Putative therapeutic results for Alzheimers and related dementias (2020) (0)
Lifelong musical activity is associated with multi-domain cognitive and brain benefits in older adults (2021) (0)
PHYSICAL AND COGNITIVE ACTIVITY AND RISK OF ALZHEIMER'S DEMENTIA IN SUBJECTIVE COGNITIVE DECLINE AND MILD COGNITIVE IMPAIRMENT (2014) (0)
IC-P2-105: A multicenter 1H-MRS study of the medial temporal lobe in Alzheimer's disease and mild cognitive impairment (2008) (0)
Cognitive and biological characteristics of stage 2 of AD in the clinical multicenter DELCODE Study (2020) (0)
Slowly progressing logopenic aphasia in a patient with a TREM2 (p.T96K) mutation (2015) (0)
CORRELATION OF CEREBROSPINAL FLUID CYTOKINES WITH CLINICAL MARKERS OF DEMENTIA IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE (2014) (0)
Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations (2017) (0)
Contents Vol. 7, 2010 (2010) (0)
Smoking upregulates α4β2∗ nicotinic acetylcholine receptors in brainstem and cerebellum (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Frank Jessen?

Frank Jessen is affiliated with the following schools:

University of Cologne
University of Bonn

Frank Jessen's Academic­Influence.com Rankings

Frank Jessen's Degrees

Why Is Frank Jessen Influential?

Frank Jessen's Published Works

Published Works

What Schools Are Affiliated With Frank Jessen?

Frank Jessen's AcademicInfluence.com Rankings